Chemical structure of Taurine

Taurine

Conditionally essential sulfur amino acid with modest, replicated cardiometabolic effects — strongest where there's a deficit to correct.

Taurine at a Glance

Taurine is a sulphur-containing amino acid, though not one used to build proteins. The body makes it from cysteine and it is abundant in shellfish, meat and fish — concentrated in the heart, retina, muscle and brain.

Its role is as a cell-volume regulator and membrane stabiliser, which is why it accumulates in exactly the tissues that work hardest and matters most when they are under load.

What It’s Used For

How It Works

Taurine is an osmolyte: it moves in and out of cells to regulate their volume, stabilising membranes under stress. In cardiac muscle it modulates calcium handling, which is the route to the blood-pressure and heart-failure effects; in the retina and brain it protects cells under metabolic load; and it conjugates bile acids, which is where the lipid effects come from.

It is dosed in grams, well tolerated, and builds up rather than acting acutely.

The full trial record is in Pharmacology & Research below.

Pharmacology & Research

Taurine is a sulfur-containing, conditionally essential amino acid — one of the most abundant free amino acids in heart, skeletal muscle, brain, and blood cells, yet unusual in that it is never built into proteins. Its evidence base is strongest and most consistent in the cardiometabolic domain: multiple meta-analyses of randomized trials show small but replicated reductions in blood pressure, triglycerides, and fasting glucose, alongside modest gains in cardiac function in heart-failure patients 2Reference 2Nie et al. · 2025Meta-analysisEffects of oral taurine supplementation on cardiometabolic risk factors: a meta-analysis and systematic review of randomized clinical trials — [meta-analysis]View study →.

Effects are clearest where there is something to correct — hypertension, dysglycemia, disease-related depletion — and thinner in already-healthy people, which is the central caveat for anyone taking it “for general wellness.” Bioavailability is not the limiting factor here (oral taurine is well absorbed); the limiter is that many trials are small and the popular associations — “calm,” focus, energy-drink benefits, anti-aging — are far softer than the cardiometabolic data. A widely publicized 2023 claim that taurine decline drives aging was directly challenged by human data in 2025.

Best-supported:modest blood-pressure reduction (SBP ≈ −4 mmHg, DBP ≈ −1.5 mmHg) pooled across ~20–25 RCTs 1,3,4Reference 1Tzang et al. · 2024Meta-analysisInsights into the cardiovascular benefits of taurine: a systematic review and meta-analysis — [meta-analysis]View study →Reference 3Tzang et al. · 2024Meta-analysisTaurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of RCTs — [meta-analysis]View study →Reference 4Guan et al. · 2020Meta-analysisThe effects of taurine supplementation on obesity, blood pressure and lipid profile: a meta-analysis of RCTs — [meta-analysis]View study →, and improvements in glycemic control (HbA1c, fasting glucose, HOMA-IR) in people with diabetes or metabolic dysfunction 5,6,7Reference 5Tao et al. · 2022Meta-analysisThe effects of taurine supplementation on diabetes mellitus in humans: a systematic review and meta-analysis — [meta-analysis]View study →Reference 6Sun et al. · 2024Meta-analysisEffect of long-term taurine supplementation on the lipid and glycaemic profile in adults with overweight or obesity: a systematic review and meta-analysis — [meta-analysis]View study →Reference 7Maleki et al. · 2020RCTThe effects of taurine supplementation on glycemic control and serum lipid profile in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial — [RCT]View study →.
Emerging / cautiously endorsed:lower triglycerides and total cholesterol 3,4,6Reference 3Tzang et al. · 2024Meta-analysisTaurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of RCTs — [meta-analysis]View study →Reference 4Guan et al. · 2020Meta-analysisThe effects of taurine supplementation on obesity, blood pressure and lipid profile: a meta-analysis of RCTs — [meta-analysis]View study →Reference 6Sun et al. · 2024Meta-analysisEffect of long-term taurine supplementation on the lipid and glycaemic profile in adults with overweight or obesity: a systematic review and meta-analysis — [meta-analysis]View study →; a small endurance-performance edge (Hedges’ g ≈ 0.40) at 1–6 g 10Reference 10Waldron et al. · 2018Meta-analysisThe effects of an oral taurine dose and supplementation period on endurance exercise performance in humans: a meta-analysis — [meta-analysis]View study →; adjunctive gains in heart-failure functional capacity and ejection fraction in small trials 1,8,9Reference 1Tzang et al. · 2024Meta-analysisInsights into the cardiovascular benefits of taurine: a systematic review and meta-analysis — [meta-analysis]View study →Reference 8Azuma et al. · 1985RCTTherapeutic effect of taurine in congestive heart failure: a double-blind crossover trial — [randomised crossover trial]View study →Reference 9Beyranvand et al. · 2011RCTEffect of taurine supplementation on exercise capacity of patients with heart failure — [RCT]View study →.
Popular but thin / overhyped:the “calm,” focus, and energy-drink cognitive benefits rest on caffeine-confounded studies where taurine’s independent contribution is hard to isolate 13,14,12Reference 13Seidl et al. · 2000Clinical trialA taurine and caffeine-containing drink stimulates cognitive performance and well-being — [clinical trial]View study →Reference 14Giles et al. · 2012RCTDifferential cognitive effects of energy drink ingredients: caffeine, taurine, and glucose — [RCT]View study →Reference 12Deng et al. · 2025Meta-analysisCaffeine and taurine: a systematic review and network meta-analysis of their individual and combined effects on physical capacity, cognitive function, and physiological markers — [network meta-analysis]View study →; anti-aging claims are almost entirely preclinical 15Reference 15Singh et al. · 2023Taurine deficiency as a driver of aging — [animal/experimental]View study →.
The honest miss / caveat:the 2023 Science “taurine deficiency drives aging” hypothesis was challenged in humans in 2025 — a cross-sectional study of 137 men aged 20–93 found circulating taurine was not associated with age or physical performance 16Reference 16Marcangeli et al. · 2025Clinical trialExperimental evidence against taurine deficiency as a driver of aging in humans — [cross-sectional human study]View study →, and an NIA-led Science analysis questioned taurine’s status as an aging biomarker 17Reference 17Fernandez et al. · 2025Is taurine an aging biomarker? — [analysis/commentary]View study →. Cardiometabolic effects are also largest in deficient or dysregulated people, so a healthy, well-fed adult should expect less.
Evidence by IndicationStrength of support · Beta

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric. Each application links down to its write-up.

Mechanisms

Target / pathwayEffectRelevant to
Cell-volume osmoregulationCytoprotective; stabilizes membranes
Cardiacmetabolicgeneral
Cardiomyocyte Ca²⁺ handlingModulates calcium flux / contractility
Heart failureblood pressure
Bile-acid conjugation (taurocholate)Promotes cholesterol → bile-acid turnover
Lipidstriglycerides
Antioxidant / taurine-chloramineDampens oxidative stress and inflammation
Metabolicvascularaging (preclinical)
Mitochondrial tRNA modification (5-taurinomethyluridine)Supports mitochondrial translation / energy metabolism
Exercisemetabolic
GABA-A / glycine receptors (weak agonism)Mild inhibitory neuromodulation
Proposed “calm” (thinly evidenced)

Pharmacokinetics

Oral taurine is absorbed via the sodium-and-chloride-dependent taurine transporter (TauT/SLC6A6) in the gut and, as a small, water-soluble molecule, has good oral bioavailability — so unlike minerals, form is not the decision-relevant variable (supplements are simply free taurine). Plasma concentrations peak roughly 1–2.5 hours after a gram-scale dose and return toward baseline within hours (elimination half-life on the order of ~1 hour), with the kidney tightly regulating excretion to defend a large tissue pool held in muscle, heart, and brain. Endogenous synthesis from cysteine (via cysteine-sulfinic-acid decarboxylase) is comparatively low in humans, which is why dietary intake and — for people eating little animal protein — supplementation measurably influence status. Food has little effect on absorption, and because plasma clears quickly, disease trials commonly split the daily dose (e.g. 500 mg–1 g, two to three times daily).

Clinical trials

Taurine has been tested in dozens of small-to-moderate randomized trials, concentrated in cardiovascular, metabolic/diabetic, and exercise settings; because it is an inexpensive, off-patent molecule, there is little large-scale industry-sponsored trial activity, and most evidence comes from investigator-led studies pooled in meta-analyses. Longevity and metabolic-aging trials in humans are only now beginning.

CompletedPlanned / ongoingTerminatedPreclinical
~40+(mostly small RCTs)~10fewextensive(animal/in vitro)

Last checked: July 2026.

Dietary Sources

Taurine is found almost exclusively in animal-source foods — it is essentially absent from plants, so intake tracks meat, fish, shellfish, and (to a lesser degree) dairy consumption. Shellfish and dark poultry meat are the richest common sources. Because humans synthesize only modest amounts endogenously (from cysteine), dietary intake meaningfully affects status, and strict vegans/vegetarians tend to have lower circulating and urinary taurine than omnivores. A typical omnivorous diet supplies on the order of tens to a few hundred milligrams per day — well below the gram-level doses used in supplement trials.

Food (approx. per 100 g)Taurine
Scallops / shellfishvery high (several hundred mg)
Dark chicken/turkey meathigh (~100–300 mg)
Fish (e.g. tuna, white fish)moderate–high
Red meat (beef, pork)moderate (~40–80 mg)
Dairy (milk)low
Plant foodsnegligible

Values are approximate and vary by species and cooking; see the NIH ODS and food-composition databases for specifics. Cooking method (boiling leaches taurine into the liquid) and a plant-based diet both lower intake.

Dosage & Intake

Taurine is conditionally essential — the body makes some, but requirements can outstrip synthesis in infancy, illness, or on a low-animal-protein diet — so there is no RDA or Adequate Intake the way there is for vitamins and minerals, and no formal Tolerable Upper Intake Level. Doses studied in research (not personal recommendations):

  • Cardiovascular / blood pressure: commonly ~1.5 g/day (e.g. 500 mg three times daily).
  • Metabolic / glycemic: often 3 g/day, sometimes up to 6 g/day.
  • Exercise: single doses of 1–6 g, typically ~1–2 g before exercise.

Because taurine is a small, water-soluble molecule that is well absorbed, form is not a meaningful variable (supplements are simply free taurine — there is no elemental-versus-compound weight issue as there is with minerals). Plasma clears within a few hours, so disease trials often split the dose across the day. These ranges are informational and reflect doses studied in research, not a personal recommendation.

Safety

Taurine is one of the better-tolerated things here — no serious adverse effects in the pooled cardiovascular and metabolic meta-analyses at 0.5–6 g/day. What matters is not the compound itself but what it adds to: it modestly lowers blood pressure and glucose, so the practical caution is with medications doing the same job.

Safety at a Glance
Low / no toxicityDrug interactions
  • Well tolerated at 0.5–6 g/day. No serious adverse effects in the pooled trials; mild nausea or loose stool at higher doses.
  • Additive with blood-pressure and glucose-lowering drugs. Monitor if combining with antihypertensives or antidiabetics.
  • Renal impairment warrants care. Taurine is renally excreted and its transporter is kidney-regulated — involve a clinician.
  • Cardiac patients should not self-treat. Heart failure and other cardiac conditions need clinician involvement.
  • No formal upper limit. Up to 6 g/day has been used in trials, but absence of a limit is not evidence of long-term safety.
Full Safety & Interactions Detail

Taurine has a low toxicity profile and was generally well tolerated in the cited trials at 0.5–6 g/day, with no serious adverse effects reported in the pooled cardiovascular and metabolic meta-analyses. The most common complaints at higher doses are mild gastrointestinal (nausea, loose stool). Key considerations:

  • Additive pharmacological effects: because taurine modestly lowers blood pressure and glucose, it could add to the effect of antihypertensive and glucose-lowering / antidiabetic medications — monitor if combining.
  • Renal handling: taurine is renally excreted and its transporter is regulated by the kidney; people with significant renal impairment should be cautious and involve a clinician.
  • Lithium (theoretical): as with other agents that affect renal handling and fluid balance, caution is reasonable, though direct interaction data are limited.
  • Cardiac patients: those with heart failure or other cardiac conditions should not self-treat and should involve a clinician.

Scope of this safety review (for honesty, not a claim):

  • Interactions assessed? Partially — screened for additive antihypertensive/antidiabetic effects, renal handling, and lithium; a comprehensive drug-interaction review (e.g. CYP-mediated) was not performed and is not expected to be a major route for this small water-soluble molecule.
  • Pregnancy/lactation assessed? Yes (limited) — dietary/physiological taurine is well established; supplemental high-dose safety is not established.
  • Upper Limit? No formal UL. Up to 6 g/day has been used in trials without serious adverse effects, but absence of a limit is not evidence that any dose is safe long-term.
Pregnancy & Lactation
Caution in pregnancy Caution while breastfeeding

Verdict: insufficient data — avoid high-dose supplementation. Taurine is a normal constituent of breast milk and is added to infant formula because infants have limited synthesis, so background dietary amounts are clearly compatible with pregnancy and lactation. However, supplemental gram-level doses have not been studied for safety in pregnant or breastfeeding people, so high-dose supplementation cannot be called safe and is best avoided pending data.

References

  1. Tzang, C. C., Lin, W. C., Lin, L. H., et al. (2024). Insights into the cardiovascular benefits of taurine: a systematic review and meta-analysis — [meta-analysis]. Nutrition Journal. https://pubmed.ncbi.nlm.nih.gov/39148075/
  2. Nie, Z., Liu, Y., Zhang, M., et al. (2025). Effects of oral taurine supplementation on cardiometabolic risk factors: a meta-analysis and systematic review of randomized clinical trials — [meta-analysis]. Nutrition Reviews. https://pubmed.ncbi.nlm.nih.gov/41275513/
  3. Tzang, C. C., Chi, L. Y., Lin, L. H., et al. (2024). Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of RCTs — [meta-analysis]. Nutrition & Diabetes. https://pubmed.ncbi.nlm.nih.gov/38755142/
  4. Guan, L., & Miao, P. (2020). The effects of taurine supplementation on obesity, blood pressure and lipid profile: a meta-analysis of RCTs — [meta-analysis]. European Journal of Pharmacology. https://pubmed.ncbi.nlm.nih.gov/32871172/
  5. Tao, X., Zhang, Z., Yang, Z., & Rao, B. (2022). The effects of taurine supplementation on diabetes mellitus in humans: a systematic review and meta-analysis — [meta-analysis]. Food Chemistry (Oxford). https://pubmed.ncbi.nlm.nih.gov/35769396/
  6. Sun, Q., Wang, J., Wang, H., et al. (2024). Effect of long-term taurine supplementation on the lipid and glycaemic profile in adults with overweight or obesity: a systematic review and meta-analysis — [meta-analysis]. Nutrients. https://pubmed.ncbi.nlm.nih.gov/39796489/
  7. Maleki, V., Alizadeh, M., Esmaeili, F., & Mahdavi, R. (2020). The effects of taurine supplementation on glycemic control and serum lipid profile in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial — [RCT]. Amino Acids. https://pubmed.ncbi.nlm.nih.gov/32472292/
  8. Azuma, J., Sawamura, A., Awata, N., et al. (1985). Therapeutic effect of taurine in congestive heart failure: a double-blind crossover trial — [randomised crossover trial]. Clinical Cardiology. https://pubmed.ncbi.nlm.nih.gov/3888464/
  9. Beyranvand, M. R., Kadkhodai Khalafi, M., Roshan, V. D., et al. (2011). Effect of taurine supplementation on exercise capacity of patients with heart failure — [RCT]. Journal of Cardiology. https://pubmed.ncbi.nlm.nih.gov/21334852/
  10. Waldron, M., Patterson, S. D., Tallent, J., & Jeffries, O. (2018). The effects of an oral taurine dose and supplementation period on endurance exercise performance in humans: a meta-analysis — [meta-analysis]. Sports Medicine. https://pubmed.ncbi.nlm.nih.gov/29546641/
  11. Deng, H., Song, T., Yin, M., et al. (2025). Does one shot work? The acute impact of a single taurine dose on exercise performance: a meta-analytic review — [meta-analysis]. Scandinavian Journal of Medicine & Science in Sports. https://pubmed.ncbi.nlm.nih.gov/40852891/
  12. Deng, H., Wang, L., Liu, P., et al. (2025). Caffeine and taurine: a systematic review and network meta-analysis of their individual and combined effects on physical capacity, cognitive function, and physiological markers — [network meta-analysis]. Journal of the International Society of Sports Nutrition. https://pubmed.ncbi.nlm.nih.gov/41032459/
  13. Seidl, R., Peyrl, A., Nicham, R., & Hauser, E. (2000). A taurine and caffeine-containing drink stimulates cognitive performance and well-being — [clinical trial]. Amino Acids. https://pubmed.ncbi.nlm.nih.gov/11140366/
  14. Giles, G. E., Mahoney, C. R., Brunyé, T. T., et al. (2012). Differential cognitive effects of energy drink ingredients: caffeine, taurine, and glucose — [RCT]. Pharmacology, Biochemistry, and Behavior. https://pubmed.ncbi.nlm.nih.gov/22819803/
  15. Singh, P., Gollapalli, K., Mangiola, S., et al. (2023). Taurine deficiency as a driver of aging — [animal/experimental]. Science. https://pubmed.ncbi.nlm.nih.gov/37289866/
  16. Marcangeli, V., Cefis, M., Hammad, R., et al. (2025). Experimental evidence against taurine deficiency as a driver of aging in humans — [cross-sectional human study]. Aging Cell. https://pubmed.ncbi.nlm.nih.gov/41061678/
  17. Fernandez, M. E., Bernier, M., Price, N. L., et al. (2025). Is taurine an aging biomarker? — [analysis/commentary]. Science. https://pubmed.ncbi.nlm.nih.gov/40472098/